The 3-month PDUFA extension is a modest negative for near-term sentiment, but the absence of safety or manufacturing issues limits downside. Traders should watch for any FDA advisory committee announcement or additional data requests ahead of the new December 27, 2026 PDUFA date. The stock may trade on pipeline sentiment until the new decision date.
Price Chart
Executive Summary
Praxis Precision Medicines announced a 3-month FDA extension of the PDUFA target action date for its relutrigine NDA (SCN2A/SCN8A DEEs) from September 27, 2026 to December 27, 2026, following the submission of additional sensitivity analyses deemed a major amendment. No new clinical studies were requested and no safety or manufacturing concerns were cited, but the delay introduces near-term uncertainty for the company's lead pipeline asset.
Key Facts
- FDA extended PDUFA target action date for relutrigine NDA by 3 months to December 27, 2026
- Extension triggered by submission of additional sensitivity analyses of existing clinical data, classified as a major amendment
- No new clinical studies were requested and no safety or manufacturing concerns were cited
- Review remains active and ongoing; company continues preparations for launch
Financial Impact
Delay of potential first commercial revenue by at least 3 months; no financial figures disclosed in filing
Risk Factors
- Potential for further FDA delays or a complete response letter at the new PDUFA date
- Competitive developments in DEE treatment landscape could erode market opportunity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001689548-26-000069 |
| Document: 0001689548-26-000069-index-headers.html | 0001689548-26-000069 |
| Document: 0001689548-26-000069-index.html | 0001689548-26-000069 |
| Document: 0001689548-26-000069.txt | 0001689548-26-000069 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 29, 2026 13w ago | 8-K | $334.79 $282.12 | ▲ +15.73% | ▲ +18.55% | $292.66 (+12.58%) |
Jun 11, 2026 16w ago | Institutional Cluster | $247.98 $351.81 | ▲ +41.87% | ▲ +37.47% | $292.66 (+18.02%) |
Jun 2, 2026 17w ago | Press Release | $278.93 $367.85 | ▲ +31.88% | ▲ +29.38% | $292.66 (+4.92%) |
May 7, 2026 21w ago | Press Release | $333.28 $305.51 | ▼ −8.33% | ▼ −12.17% | $292.66 (−12.19%) |
May 4, 2026 21w ago | Press Release | $333.30 $307.75 | ▼ −7.67% | ▼ −10.41% | $292.66 (−12.19%) |
Apr 14, 2026 24w ago | Press Release | $343.60 $333.12 | ▼ −3.05% | ▼ −11.57% | $292.66 (−14.83%) |
Apr 6, 2026 25w ago | Press Release | $310.11 $319.60 | ▲ +3.06% | ▼ −10.41% | $292.66 (−5.63%) |
Mar 30, 2026 26w ago | Press Release | $322.19 $327.79 | ▲ +1.74% | ▼ −10.64% | $292.66 (−9.17%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access